تُستخدم كسارة الفك PEW في الغالب لإنتاج قطع كبيرة من الخام، مع حجم جزيئات التغذية: 0-720 مم.
اقرأ المزيد
تستخدم كسارة التأثير PFW في الغالب لمعالجة الصخور اللينة، وحجم جزيئات التغذية هو: 0-350 مم.
اقرأ المزيد
تستخدم كسارة المخروطية HST في مرحلة التكسير المتوسطة للصخور الصلبة، مع حجم جزيئات التغذية: 0-560 مم.
اقرأ المزيد
مزودة بمحطات تكسير خشنة ومتوسطة ودقيقة أكثر كفاءة، ومحطات متنقلة لتشكيل الرمل والغربلة، وتغطي القدرة الإنتاجية 100-500 طن/ساعة.
اقرأ المزيد
[PDF]If adequate pain relief is not attained with a 75 mg NUCYNTA tablet every 4 hours, increase the dose to 100 mg every 4 hours to maintain adequate analgesia with acceptable tolerability. Do not exceed a maximum single dose of 100 mg. The maximum daily dose is 7.5 mg/kg/day (i.e., six 1.25 mg/kg doses over 24 hours).
سؤال
More about Nucynta ( tapentadol ) Ratings & Reviews. Morphine has an average rating of 7.5 out of 10 from a total of 364 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 13% reported a negative effect. Nucynta has an average rating of 6.2 out of 10 from a total of 269 ratings on Drugs.com. 51% of reviewers reported a
سؤال
174; ER (Tapentadol Extended-Release Tablets) Receives
Raritan, N.J., August 26, 2011--Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved NUCYNTA &سؤال
DrugBank Accession Number. DB06204. Background. Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake. 2, 3. Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved
سؤال
32;NUCYNTA oral solution exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient’s risk before prescribing and monitor regularly for these behaviors and conditions. ( 5.2) Serious, life-threatening, or fatal respiratory depression may occur.
سؤال
taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking NUCYNTA ER with certain other medicines can cause serious side effects. When taking NUCYNTA ER: Do not change your dose. Take NUCYNTA ER exactly as prescribed by your healthcare provider. Use the lowest effective dose for the shortest time needed.
سؤال
32;In general: Immediate-release tablet (Nucynta) Acute pain: The typical starting dose is 50 mg to 100 mg by mouth every 4 to 6 hours as needed for pain. Extended-release tablet (Nucynta ER) Chronic pain including diabetic nerve pain: The typical starting dose is 50 mg by mouth every 12 hours (twice a day).
سؤال
32;NUCYNTA (tapentadol) tablets are a mu-opioid receptor agonist, available in immediate-release film-coated tablets for oral administration, containing 58.24, 87.36 and 116.48 mg of tapentadol 12.1 Mechanism of Action-Tapentadol is a centrally-acting synthetic analgesic. The exact mechanism of action is unknown.
سؤال
Nucynta has an average rating of 6.2 out of 10 from a total of 269 ratings on Drugs.com. 51% of reviewers reported a positive effect, while 30% reported a negative effect. Tramadol has an average rating of 7.0 out of 10 from a total of 1842 ratings on Drugs.com. 62% of reviewers reported a positive effect, while 24% reported a negative effect.
سؤال
32;NUCYNTA Tablets are available in the following strengths and packages. All tablets are round and biconvex-shaped. 50 mg tablets are yellow and debossed with "O-M" on one side and "50" on the other side,
سؤال
174; ER (tapentadol) Extended-Release
Raritan, N.J., August 29 , 2012 – Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for NUCYNTA &سؤال
32;Serious side effects of Nucynta. Along with its needed effects, tapentadol (the active ingredient contained in Nucynta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention. Check with your doctor immediately if any of the following side effects occur while taking
سؤال
PHARMACOKINETICS. Tapentadol is rapidly absorbed, with a maximum serum concentration (C max) typically observed between 1.25 and 1.5 hours. 7 Dose-proportional increases in the C max and area-under-the-curve (AUC) values of tapentadol have been observed above the 50- to 150-mg dose range, suggesting linear pharmacokinetics.
سؤال
32;Nucynta; Nucynta ER; Descriptions. Tapentadol oral solution and tablet are used to treat pain severe enough to require opioid treatment and when other pain medicines did not work well enough or cannot be tolerated. The extended-release tablet is used to treat severe pain, including pain caused by nerve damage from diabetes.
سؤال
Tapentadol 50mg, 100mg, 150mg, 200mg, 250mg; ext-rel tabs. Nucynta ER Tablets are supplied in bottles of 60, and are available in the following strengths: 50 mg extended-release tablets are white
سؤال
Nausea, vomiting, constipation, dizziness, drowsiness, dry mouth, increased sweating, or tiredness may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly. To
سؤال
ozanimod. ozanimod increases toxicity of tapentadol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because
سؤال
Nucynta has an average rating of 6.2 out of 10 from a total of 269 ratings on Drugs.com. 51% of reviewers reported a positive effect, while 30% reported a negative effect. Tramadol has an average rating of 7.0 out of 10 from a total of 1842 ratings on Drugs.com. 62% of reviewers reported a positive effect, while 24% reported a negative effect.
سؤال
32;NUCYNTA ER (tapentadol) is an opioid agonist, supplied in extended-release film-coated tablets for oral administration, containing 58.24, 116.48, 174.72, 232.96, and 291.20 mg of tapentadol hydrochloride in each tablet strength, corresponding to 50, 100, 150, 200, and 250 mg of tapentadol free-base, respectively.
سؤال
[PDF]NUCYNTA oral solution exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk
سؤال
Tapentadol ER (Nucynta Extended-Release) is indicated for the management of patients with pain severe enough to require daily, continuous, long-term opioid treatment, and that is opioid responsive,
سؤال
Comparing Nucynta vs Oxycodone. Nucynta (tapentadol) Oxycodone. Prescription only. Prescribed for Pain. Nucynta may also be used for purposes not listed in this medication guide. Prescription only. Oxycodone is a potent pain-relieving medicine that should be reserved for mainly cancer-related pain.
سؤال
Chronic pain is generally defined as a painful condition persisting for several months or longer. In terms of approach to management, chronic pain can be broadly classified as either cancer-related pain or non-cancer pain. Common causes or types of chronic non-cancer pain include osteoarthritis (OA), back pain, fibromyalgia, post-surgical chronic pain, and
سؤال
174; was studied primarily in placebo- and active-controlled studies (n = 2266, and n = 2944, respectively). The population was 18 to 85 years old (mean age 46 years), 68% were female, 75% white and 67% were postoperative. Most patients received NUCYNTA&سؤال
Nucynta ER has a Health Canada indication for the management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Nucynta ER is an opioid analgesic. It is available as 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg ER tablets and
سؤال
32;Initial Dosage. Initiate treatment with NUCYNTA oral solution in a dosing range of 50 mg (2.5 mL) to 100 mg (5 mL) every 4 to 6 hours as needed for pain. On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate pain relief is not attained with the first dose.
سؤال
[PDF]NUCYNTA tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing NUCYNTA tablets, and monitor all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1)].
سؤال
174; ER in patients with severe hepatic impairment (Child-Pugh Score 10–15) is not recommended.. In patients with moderate hepatic impairment (Child-Pugh Score 7 to 9), initiate treatment using 50 mg NUCYNTA &سؤال174; ER, an oral analgesic taken twice daily, for the management of moderate to severe chronic pain in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
سؤال
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. Clinical Review Report: Tapentadol Hydrochloride Extended-Release Tablet (Nucynta Extended-Release): (Paladin Labs Inc.): Indication: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and
سؤال
تتمتع شركتنا بتاريخ يمتد لأكثر من 30 عامًا وشكلت تدريجيًا نظامًا كاملاً للبحث والتطوير والإنتاج والمبيعات والخدمة لتلبية احتياجات الإنتاج للمستخدمين بشكل أفضل.
آلة تكسير الحصى بقدرة 45-1200 طن/ساعة بسعر مناسب، يرجى الاتصال بنا إذا لزم الأمر.
احصل على عرض أسعار
